eligibility_summary
Eligible: Adults 18–75 with histologically/cytologically confirmed advanced clear‑cell RCC, recurrent/metastatic after ≥2 prior lines, measurable disease (RECIST 1.1), ECOG 0–1, >12‑week life expectancy, tumor tissue available, adequate organ function, negative pregnancy test and contraception. Exclude: pregnancy/lactation, HIV, active infection/autoimmunity, serious psych/medical illness, recent other cancer, systemic steroids, recent anti‑CD70/cell or IO/targeted/chemo, drug allergy, CNS mets, significant cardiac disease, transplant, or per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions and mechanisms: CGC729 is a CD70-directed CAR-NKT cellular therapy (engineered natural killer T cells). The CAR enables NKT cells to recognize CD70 on tumor cells, triggering cytotoxic killing (perforin/granzyme) and cytokine-driven anti-tumor activity, with potential remodeling of the tumor microenvironment. Patients receive lymphodepletion with cyclophosphamide (alkylating agent) and fludarabine (purine analog) to reduce host lymphocytes/regulatory cells and enhance CAR-NKT expansion and persistence. Targets: CD70-expressing renal cell carcinoma cells and the CD70/CD27 axis, effector pathways include CAR-mediated T-cell/NKT cytotoxicity and immune activation following lymphodepletion. Phase I, single-arm dose-escalation in relapsed/metastatic RCC.